Larvol Delta - Phase-2-Platform-Study-of-Novel-Immunotherapy-Combinations-as-FirstLine-Treatment-in-Participants-With-PDL1-Positive-RecurrentMetastatic-Squamous-Cell-Carcinoma-of-the-Head-and-Neck

Jemperli (dostarlimab-gxly) - GSK

GSK6097608 - GSK

http://clinicaltrials.gov/ct2/show/NCT06062420

Oct 2, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next